Clinical Trial Update: ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating ONC201 for relapsed or refractory acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, or hi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• ONC201 (ONC201)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: RECRUITING